Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence

References

1. 1.↵
   1. Wilson N,
   2. Kariisa M,
   3. Seth P,
   4. Smith H,
   5. Davis NL

   . Drug and opioid-involved overdose deaths—United States, 2017-2018. MMWR Morb Mortal Wkly Rep 2020;69:290–7.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Strickler GK,
   2. Kreiner PW,
   3. Halpin JF,
   4. Doyle E,
   5. Paulozzi LJ

   . Opioid prescribing behaviors—prescription behavior surveillance system, 11 states, 2010-2016. MMWR Surveill Summ 2020;69:1–14.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Schieber LZ,
   2. Guy GP Jr.,
   3. Seth P,
   4. Losby JL

   . Variation in adult outpatient opioid prescription dispensing by age and sex—United States, 2008-2018. MMWR Morb Mortal Wkly Rep 2020;69:298–302.

   OpenUrl
4. 4.↵
   1. Lembke A

   . Tapering long-term opioid therapy. Am Fam Physician 2020;101:49–52.

   OpenUrl
5. 5.↵
   1. Lembke A,
   2. Humphreys K,
   3. Newmark J

   . Weighing the risks and benefits of chronic opioid therapy. Am Fam Physician 2016;93:982–90.

   OpenUrl
6. 6.↵
   1. Manhapra A,
   2. Arias AJ,
   3. Ballantyne JC

   . The conundrum of opioid tapering in long-term opioid therapy for chronic pain: a commentary. Subst Abus 2018;39:152–61.

   OpenUrl
7. 7.↵
   1. Darnall BD,
   2. Juurlink D,
   3. Kerns RD,
   4. et al

   . International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Med 2019;20:429–33.

   OpenUrl
8. 8.↵
   1. Dowell D,
   2. Haegerich TM,
   3. Chou R

   . CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 2016;315:1624–45.

   OpenUrlCrossRefPubMed
9. 9.↵
   American Psychiatric Association, Diagnostic and statistical manual of mental disorders: DSM-5, fifth edition. ed. Arlington (VA): American Psychiatric Association; 2013.
10. 10.↵
    1. Chou R,
    2. Ballantyne J,
    3. Lembke A

    . Rethinking opioid dose tapering, prescription opioid dependence, and indications for buprenorphine. Ann Intern Med 2019;171:427.

    OpenUrlCrossRefPubMed
11. 11.↵
    Health and Human Services. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. Washington (DC): Health and Human Services; 2019.
12. 12.↵
    1. Foster B,
    2. Twycross R,
    3. Mihalyo M,
    4. Wilcock A

    . Buprenorphine. J Pain Symptom Manage 2013;45:939–49.

    OpenUrl
13. 13.↵
    1. Sansone RA,
    2. Sansone LA

    . Buprenorphine treatment for narcotic addiction: not without risks. Innov Clin Neurosci 2015;12:32–6.

    OpenUrl
14. 14.↵
    1. Khanna IK,
    2. Pillarisetti S

    . Buprenorphine—an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res 2015;8:859–70.

    OpenUrlPubMed
15. 15.↵
    1. Gunderson EW

    . Buprenorphine induction: a major barrier for physician adoption of office-based opioid dependence treatment. J Addict Med 2011;5:304–5.

    OpenUrlPubMed
16. 16.↵
    1. Darnall BD,
    2. Mackey SC,
    3. Lorig K,
    4. et al

    . Comparative effectiveness of cognitive behavioral therapy for chronic pain and chronic pain self-management within the context of voluntary patient-centered prescription opioid tapering: the EMPOWER study protocol. Pain Med 2019;21(8):1523–1531.

    OpenUrl
17. 17.↵
    1. Hammig R,
    2. Kemter A,
    3. Strasser J,
    4. et al

    . Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil 2016;7:99–105.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Rozylo J,
    2. Mitchell K,
    3. Nikoo M,
    4. et al

    . Case report: successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. Addict Sci Clin Pract 2020;15:2.

    OpenUrl
19. 19.↵
    1. Randhawa PA,
    2. Brar R,
    3. Nolan S

    . Buprenorphine-naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market. Cmaj 2020;192:E73. In:. Vol Canada.

    OpenUrlFREE Full Text
20. 20.↵
    1. Gudin J,
    2. Fudin J

    . A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther 2020;9:41–54.

    OpenUrlPubMed
21. 21.↵
    1. De Aquino JP,
    2. Fairgrieve C,
    3. Klaire S,
    4. Garcia-Vassallo G

    . Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient Veteran Affairs setting. J Addict Med 2020;14(5):e271–e273.
22. 22.↵
    1. Terasaki D,
    2. Smith C,
    3. Calcaterra SL

    . Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol. Pharmacotherapy 2019;39:1023–9.

    OpenUrl
23. 23.↵
    1. Raheemullah A,
    2. Lembke A

    . Initiating opioid agonist treatment for opioid use disorder in the inpatient setting: a teachable moment. JAMA Intern Med 2019;179:427–8.

    OpenUrl
24. 24.↵
    1. Martin L,
    2. Lennox R,
    3. Regenstreif L,
    4. O’shea T

    . Case report: “striving to skip the withdrawal” using buprenorphine–naloxone microdosing for hospitalized patients. Cana J Addict 2019;10:35–40.

    OpenUrl
25. 25.↵
    1. Lee DS,
    2. Hann JE,
    3. Klaire SS,
    4. Nikoo M,
    5. Negraeff MD,
    6. Rezazadeh-Azar P

    . Rapid induction of buprenorphine/naloxone for chronic pain using a microdosing regimen: a case report. A A Pract 2019;14(2):44–47.

    OpenUrl
26. 26.↵
    1. Klaire S,
    2. Zivanovic R,
    3. Barbic SP,
    4. Sandhu R,
    5. Mathew N,
    6. Azar P

    . Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict 2019;28:262–5.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Becker WC,
    2. Frank JW,
    3. Edens EL

    . A switching from high-dose, long-term opioids to buprenorphine: a case series. Ann Intern Med 2020;173(1):70–71.

    OpenUrl
28. 28.↵
    1. Koob GF

    . Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry 2020;87:44–53.

    OpenUrl
29. 29.↵
    1. Walley AY,
    2. Alperen JK,
    3. Cheng DM,
    4. et al

    . Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med 2008;23:1393–8. Vol.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Zubieta J,
    2. Greenwald MK,
    3. Lombardi U,
    4. et al

    . Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 2000;23:326–34.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Davis MP,
    2. Digwood G,
    3. Mehta Z,
    4. McPherson ML

    . Tapering opioids: a comprehensive qualitative review. Ann Palliat Med 2020;9:586–610.

    OpenUrl
32. 32.↵
    1. Slavova S,
    2. Rock P,
    3. Bush HM,
    4. Quesinberry D,
    5. Walsh SL

    . Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend 2020;214:108176.

    OpenUrlPubMed
33. 33.↵
    1. Harris M,
    2. Johnson S,
    3. Mackin S,
    4. Saitz R,
    5. Walley AY,
    6. Taylor JL

    . Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med 2020;14(4):e136–e138.

    OpenUrl
34. 34.↵
    1. Dunlop A,
    2. Lokuge B,
    3. Masters D,
    4. et al

    . Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J 2020;17:26.

    OpenUrlPubMed
35. 35.↵
    1. Becker WC,
    2. Fiellin DA

    . When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med 2020;173:59–60.

    OpenUrlPubMed